Androgens and bone metabolism;Androgènes et métabolisme osseux

Revue du Rhumatisme (Edition Francaise)

Volumn 72, Issue 5 SPEC. ISS., 2005, Pages 383-387

  Alexandre, Christian ^a  

^a SERVICE DE NEUROLOGIE   (France)

Author keywords

Androgens; Estrogens; Men; Osteoporosis; Prostate cancer

Indexed keywords

EID: 24044520323     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rhum.2004.04.010     Document Type: Short Survey

References (54)

1. H.W. Wahner, W.L. Dunn, and B.L. Riggs Noninvasive bone mineral measurements Semin Nucl Med 13 1983 282 289
2. J.A. Kanis, L.J. Melton 3rd, C. Christiansen, C.C. Johnston, and N. Khaltaev The diagnosis of osteoporosis J Bone Miner Res 9 1994 1137 1141
3. L. Mosekilde, and L. Mosekilde Sex differences in age-related changes in vertebral body size, density and biomechanical competence in normal individuals Bone 11 1990 67 73
4. E. Seeman Periosteal bone formation-a neglected determinant of bone strength N Engl J Med 349 2003 320 323
5. J.R. Center, T.V. Nguyen, D. Schneider, P.N. Sambrook, and J.A. Eisman Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 1999 878 882
6. T.V. Nguyen, J.A. Eisman, P.J. Kelly, and P.N. Sambrook Risk factors for osteoporotic fractures in elderly men Am J Epidemiol 144 1996 255 263
7. E. Legrand, I. Degasne, D. Chappard, M.F. Basle, and M. Audran Ostéoporoses Encycl. Med Chir 1999 Elsevier Paris 15 Appareil locomoteur, 14-027-G10
8. S. Bord, A. Horner, S. Beavan, and J. Compston Estrogen receptors alpha and beta are differentially expressed in developing human bone J Clin Endocrinol Metab 86 2001 2309 2314
9. D. Vanderschueren, and R. Bouillon Androgens and bone Calcif Tissue Int 56 1995 341 346
10. S. Kousteni, T. Bellido, L.I. Plotkin, C.A. O'Brien, D.L. Bodenner, and L. Han Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity Cell 104 2001 719 730
11. J.S. Finkelstein, A. Klibanski, R.M. Neer, S.L. Greenspan, D.I. Rosenthal, and W.F. Crowley Osteoporosis in men with idiopathic hypogonadotropic hypogonadium Ann Int Med 106 1987 354 361
12. F. Albright, E. Bloomberg, and P.H. Smith Post-menopausal osteoporosis Trans Assoc Am Phys 55 1940 298 305
13. H.M. Behre, S. Kliesch, E. Leifke, T.M. Link, and E. Nieschlag Long-term effect of testosterone therapy on bone mineral density in hypogonadal men J Clin Endocrinol Metab 82 1997 2386 2390
14. R. Lindsay, J.C. Gallagher, M. Kleerekoper, and J.H. Pickar Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women JAMA 287 2002 2668 2676
15. E.P. Smith, J. Boyd, G.R. Frank, H. Takahashi, R.A. Cohen, and B. Specker Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man N Engl. J. Med 331 1994 1056 1061
16. A. Morishima, M.M. Grumbach, E.R. Simpson, C. Fisher, and K. Qin Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens J Clin Endocrinol Metab 80 1995 3689 3698
17. J.P. Bilezikian, A. Morishima, S. Bell, and M.M. Grumbach Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency N Engl J Med 339 1998 599 603
18. C. Carani, K. Qin, M. Simoni, M. Faustini-Fustini, S. Serpente, and J. Boyd Effect of testosterone and estradiol in a man with aromatase deficiency N Engl J Med 337 1997 91 95
19. V. Rochira, M. Faustini-Fustini, A. Balestrieri, and C. Carani Estrogen replacement therapy in a man with congenital aromatase deficiency: effects of different doses of transdermal estradiol on bone mineral density and hormonal parameters J Clin Endocrinol Metab 85 2000 1841 1845
20. N.A. Sims, P. Clement-Lacroix, D. Minet, C. Fraslon-Vanhulle, M. Gaillard-Kelly, and M. Resche-Rigon A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice J Clin Invest 111 2003 1319 1327
21. R. Marcus, D. Leary, D.L. Schneider, E. Shane, M. Favus, and C.A. Quigley The contribution of testosterone to skeletal development and maintenance: lessons from the androgen insensitivity syndrome J Clin Endocrinol Metab 85 2000 1032 1037
22. M.C. De Vernejoul, and M. Cohen Solal Estrogens, androgens, and osteoporosis in men Ann Endocrinol (Paris) 64 2003 137 140
23. S. Khosla, L.J. Melton 3rd, E.J. Atkinson, W.M. O'Fallon, G.G. Klee, and B.L. Riggs Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen J Clin Endocrinol Metab 83 1998 2266 2274
24. G.A. Greendale, S. Edelstein, and E. Barrett-Connor Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study J Bone Miner Res 12 1997 1833 1843
25. C.W. Slemenda, C. Longcope, L. Zhou, S.L. Hui, M. Peacock, and C.C. Johnston Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens J Clin Invest 100 1997 1755 1759
26. E. Legrand, C. Hedde, Y. Gallois, I. Degasne, F. Boux de Casson, and E. Mathieu Osteoporosis in men: a potential role for the sex hormone binding globulin Bone 29 2001 90 95
27. S. Khosla, L.J. Melton 3rd, E.J. Atkinson, and W.M. O'Fallon Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men J Clin Endocrinol Metab 86 2001 3555 3561
28. I. Van Pottelbergh, S. Goemaere, and J.M. Kaufman Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age J Clin Endocrinol Metab 88 2003 3075 3081
29. S. Khosla, L.J. Melton 3rd, and B.L. Riggs Clinical review 144: Estrogen and the male skeleton J Clin Endocrinol Metab 87 2002 1443 1450
30. P. Szulc, F. Munoz, B. Claustrat, P. Garnero, F. Marchand, and F. Duboeuf Bio available estradiol may be an important determinant of osteoporosis in men: the MINOS study J Clin. Endocrinol Metab 86 2001 192 199
31. A. Falahati-Nini, B.L. Riggs, E.J. Atkinson, W.M. O'Fallon, R. Eastell, and S. Khosla Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men J Clin Invest 106 2000 1553 1560
32. B.Z. Leder, K.M. Le Blanc, D.A. Schoenfeld, R. Eastell, and J.S. Finkelstein Differential effects of androgens and estrogens on bone turn-over in hormonal men J Clin Endocrinol Metab 88 2003 204 210
33. C. Huggins, and C. Hodges Studies in prostate cancer. I. The effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
34. E. Seeman Pathogenesis of bone fragility in women and men Lancet 359 2002 1841 1850
35. J. Jackson, M. Riggs, and A. Spiekerman Testosterone deficiency as a risk factor for hip fractures in men: a case-control study Am J Med Sci 304 1992 4 8
36. H. Daniell Osteoporosis after orchiectomy for prostate cancer J Urol 157 1997 439 444
37. L. Dahmani, B. Wagner, C. Auzanneau, J. Irani, and B. Dore Prevalence of osteoporotic fractures in patients treated by androgen blockade for prostate cancer Prog Urol 13 2003 73 78
38. H.W. Daniell Osteoporosis due to androgen deprivation therapy in men with prostate cancer Urology 58 Suppl 1 2001 101 107
39. L.J. Melton 3rd, K.I. Alothman, S. Khosla, S.J. Achenbach, A.L. Oberg, and H. Zincke Fracture risk following bilateral orchiectomy J Urol 169 2003 1747 1750
40. J.T. Wei, M. Gross, C.A. Jaffe, K. Gravlin, M. Lahaie, and G.J. Faerber Androgen deprivation therapy for prostate cancer results in significant loss of bone density Urology 54 1999 607 611
41. D.M. Preston, J.I. Torrens, P. Harding, R.S. Howard, W.E. Duncan, and D.G. McLeod Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss Prostate Cancer Prostatic Dis 5 2002 304 310
42. B.J. Kiratli, S. Srinivas, I. Perkash, and M.K. Terris Progressive decrease in bone density over ten years of androgen deprivation therapy in patients with prostate cancer Urology 57 2001 127 132
43. M.R. Smith Management of treatment-related osteoporosis in men with prostate cancer Cancer Treat Rev 29 2003 211 218
44. M.R. Smith, F.J. McGovern, A.L. Zietman, M.A. Fallon, D.L. Hayden, and D.A. Schoenfeld Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 2001 948 955
45. M.R. Smith, J. Eastham, D.M. Gleason, D. Shasha, S. Tchekmedyian, and N. Zinner Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2003 2008 2012
46. T.H. Diamond, J. Winters, A. Smith, P. De Souza, J.H. Kersley, and W.J. Lynch The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study Cancer 92 2001 1444 1450
47. L. Vandenput, S. Boonen, E. Van Herck, J.V. Swinnen, R. Bouillon, and D. Vanderschueren Evidence from the aged orchidectomized male rat model that 17beta-estradiol is a more effective bone-sparing and anabolic agent than 5alpha-dihydrotestosterone J Bone Miner Res 17 2002 2080 2086
48. A. Vermeulen Androgen replacement therapy in the aging male-a critical evaluation J Clin Endocrinol Metab 86 2000 2380 2390
49. S. Gonnelli, C. Cepollaro, A. Montagnani, D. Bruni, C. Caffarelli, and M. Breschi Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study Calcif Tissue Int 73 2003 133 139
50. K. Hanada, K. Furuya, N. Yamamoto, H. Nejishima, K. Ichikawa, and T. Nakamura Bone Anabolic Effects of S-40503, a Novel Nonsteroidal Selective Androgen Receptor Modulator (SARM), in Rat Models of Osteoporosis Biol Pharm Bull 26 2003 1563 1569
51. M.R. Zacharin, J. Pua, and S. Kanumakala Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism Clin Endocrinol (Oxf) 58 2003 691 695
52. B. Ongphiphadhanakul, S. Thamprajamchit, S. Chanprasertyothin, L. Chailurkit, and R. Rajatanavin Effect of estrogen replacement on insulin sensitivity, serum lipid and bone resorption marker in hypogonadal males Maturitas 42 2002 85 89
53. P.M. Doran, B.L. Riggs, E.J. Atkinson, and S. Khosla Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men J Bone Miner Res 16 2001 2118 2125
54. I.Y. Kim, H. Seong do, B.C. Kim, D.K. Lee, A.T. Remaley, and F. Leach Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway Cancer Res 62 2002 3649 3653